Juvista (INN: Avotermin – an injectable solution of human active recombinant transforming growth factor beta 3 (TGFβ3)).
The Juvista EU phase 3 trial (REVISE) did not meet its primary or secondary efficacy endpoints as reported on 11 February 2011.
Printer-friendly version